JNK1 is required for T cell-mediated immunity against Leishmania major infection
| dc.contributor.author | Constant, Stephanie L. | |
| dc.contributor.author | Dong, Chen | |
| dc.contributor.author | Yang, Derek D. | |
| dc.contributor.author | Wysk, Mark Allen | |
| dc.contributor.author | Davis, Roger J. | |
| dc.contributor.author | Flavell, Richard A. | |
| dc.date | 2022-08-11T08:08:56.000 | |
| dc.date.accessioned | 2022-08-23T16:13:14Z | |
| dc.date.available | 2022-08-23T16:13:14Z | |
| dc.date.issued | 2000-08-18 | |
| dc.date.submitted | 2008-08-27 | |
| dc.identifier.citation | <p>J Immunol. 2000 Sep 1;165(5):2671-6.</p> | |
| dc.identifier.issn | 0022-1767 (Print) | |
| dc.identifier.doi | 10.4049/jimmunol.165.5.2671 | |
| dc.identifier.pmid | 10946297 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14038/33574 | |
| dc.description.abstract | c-Jun N-terminal kinase (JNK) is a mitogen-activated protein kinase that plays important regulatory roles in helper T cell differentiation. In the current study, we used Jnk1-deficient mice to examine the function of JNK during an in vivo pathogenic infection, leishmaniasis, which is strongly influenced by Th1/Th2 effector mechanisms. The data show that Jnk1-deficient mice, despite their usually genetically resistant background, were unable to resolve Leishmania infections. Jnk1-/- mice displayed reduced delayed-type hypersensitivity in response to the pathogen, which was associated with a T cell defect. We found that, although these mice can direct an apparent Th1-response, there is also simultaneous generation of Leishmania-specific Th2 responses, which possibly down-modulate protective Th1-mediated immune function. These findings demonstrate that the negative regulation of Th2 cytokine production by the JNK1 signaling pathway is essential for generating Th1-polarized immunity against intracellular pathogens, such as Leishmania major. | |
| dc.language.iso | en_US | |
| dc.relation | <p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10946297&dopt=Abstract">Link to article in PubMed</a></p> | |
| dc.relation.url | https://doi.org/10.4049/jimmunol.165.5.2671 | |
| dc.subject | Animals; CD4-Positive T-Lymphocytes; Cell Differentiation; Cytokines; Hypersensitivity, Delayed; Immunity, Cellular; Leishmania major; Leishmaniasis, Cutaneous; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; T-Lymphocyte Subsets; Th1 Cells; Th2 Cells | |
| dc.subject | Life Sciences | |
| dc.subject | Medicine and Health Sciences | |
| dc.title | JNK1 is required for T cell-mediated immunity against Leishmania major infection | |
| dc.type | Journal Article | |
| dc.source.journaltitle | Journal of immunology (Baltimore, Md. : 1950) | |
| dc.source.volume | 165 | |
| dc.source.issue | 5 | |
| dc.identifier.legacycoverpage | https://escholarship.umassmed.edu/gsbs_sp/244 | |
| dc.identifier.contextkey | 606042 | |
| html.description.abstract | <p>c-Jun N-terminal kinase (JNK) is a mitogen-activated protein kinase that plays important regulatory roles in helper T cell differentiation. In the current study, we used Jnk1-deficient mice to examine the function of JNK during an in vivo pathogenic infection, leishmaniasis, which is strongly influenced by Th1/Th2 effector mechanisms. The data show that Jnk1-deficient mice, despite their usually genetically resistant background, were unable to resolve Leishmania infections. Jnk1-/- mice displayed reduced delayed-type hypersensitivity in response to the pathogen, which was associated with a T cell defect. We found that, although these mice can direct an apparent Th1-response, there is also simultaneous generation of Leishmania-specific Th2 responses, which possibly down-modulate protective Th1-mediated immune function. These findings demonstrate that the negative regulation of Th2 cytokine production by the JNK1 signaling pathway is essential for generating Th1-polarized immunity against intracellular pathogens, such as Leishmania major.</p> | |
| dc.identifier.submissionpath | gsbs_sp/244 | |
| dc.contributor.department | Program in Molecular Medicine | |
| dc.contributor.department | Graduate School of Biomedical Sciences | |
| dc.source.pages | 2671-6 |